← Back to Search

Short-Acting Beta Agonist

Albuterol eMDPI DS for Chronic Obstructive Pulmonary Disease

N/A
Waitlist Available
Led By Michael B Drummond, MD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial is testing how different COPD patients respond to taking ProAir Digihaler, a medication delivered via inhaler, in their everyday lives.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease (COPD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Variability in Peak Inspiratory Flow (PIF)
Variability in Peak Inspiratory Flow (PIF) as Measured by Coefficient of Variation
Secondary outcome measures
Correlation of Self-Reported Inhaler Use With Actual Inhaler Use
Mean Variability in Inhalation Volume
Variability in Inhalation Volume as Measured by Coefficient of Variation

Side effects data

From 2021 Phase 4 trial • 333 Patients • NCT03890666
7%
Asthma
1%
Ovarian cancer
100%
80%
60%
40%
20%
0%
Study treatment Arm
Digital System (DS)
Concurrent Control (CC)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Albuterol eMDPI DS (ProAir® Digihaler®)Experimental Treatment1 Intervention
This arm will receive the intervention of the Albuterol eMDPI DS for three months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Salbutamol
FDA approved

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,504 Previous Clinical Trials
4,187,608 Total Patients Enrolled
Wake Forest University Health SciencesOTHER
1,239 Previous Clinical Trials
1,004,129 Total Patients Enrolled
Teva Branded Pharmaceutical Products R&D, Inc.Industry Sponsor
251 Previous Clinical Trials
3,485,322 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the research project open to new participants at this time?

"According to the data displayed on clinicaltrials.gov, this medical study is not accepting applications at present. The trial was initially submitted on March 1st 2022 and most recently modified on December 6th of that same year. Although this particular trial isn't enrolling participants right now, there are 401 different trials currently looking for volunteers."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
2022. "Digihaler in Chronic Obstructive Pulmonary Disease (COPD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05241288.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top